Tara Kimbason, MD
Neurology · Norfolk, VANPI 1427324888
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $76,400 of the $119,403 with a category attached, or 64.0%. MDD US Operations, LLC accounts for 79.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $75,194 and has fallen 84.4% since, to $11,763 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 428 payments — averaging $278.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$95K
- Insightec,inc$8K
- Medtronic$5K
- Boston Scientific$3K
- Abbott$3K
- Amneal Pharmaceuticals LLC$2K
- plus $3K from 19 others
What the payments were for
- Consulting fees$2,4202%
- Speaking & faculty fees$76,40064%
- Travel & lodging$29,58825%
- Food & beverage$10,8849%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 172 | $95,409 |
| Insightec,inc | 30 | $8,376 |
| Medtronic(2 entities) | 38 | $5,028 |
| Boston Scientific | 23 | $2,874 |
| Abbott | 25 | $2,871 |
| Amneal Pharmaceuticals LLC | 25 | $2,166 |
| AbbVie(2 entities) | 36 | $493 |
| Supernus Pharmaceuticals, Inc. | 2 | $280 |
| Teva Pharmaceuticals USA, Inc. | 11 | $254 |
| Acadia Pharmaceuticals Inc | 13 | $241 |
| Lundbeck LLC | 9 | $219 |
| Kyowa Kirin, Inc. | 9 | $134 |
| Biohaven Pharmaceuticals, Inc. | 2 | $132 |
| Adamas Pharmaceuticals, Inc. | 7 | $126 |
| Greenwich Biosciences, Inc. | 1 | $121 |
| Sunovion Pharmaceuticals Inc. | 5 | $112 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $112 |
| Neurocrine Biosciences, Inc. | 6 | $108 |
| AstraZeneca | 1 | $106 |
| Acorda Therapeutics, Inc | 4 | $85 |
| UCB, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $44 |
| Pfizer | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Biogen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GOCOVRI$60,132
- APOKYN$24,007
- Exablate$7,461
- MYOBLOC$6,704
- INFINITY$2,346
- VERCISE$2,203
- PERCEPT PC BRAINSENSE$2,005
- RYTARY$1,800
- ACTIVA$1,070
- Xadago$500
- INTELLIS ADAPTIVESTIM$400
- SYNCHROMEDII$349
- Epidiolex$121
- NURTEC ODT$118
How this compares
$119,403 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 80 | $185,386 |
| RytaryCarbidopa/Levodopa | 132 | $143,410 |
| IngrezzaValbenazine Tosylate | 13 | $105,344 |
| NuplazidPimavanserin Tartrate | 23 | $99,392 |
| AustedoDeutetrabenazine | 12 | $58,534 |
| Droxidopa | 15 | $33,983 |
| Austedo XrDeutetrabenazine | 11 | $27,554 |
| NeuproRotigotine | 16 | $25,526 |
| NourianzIstradefylline | 11 | $20,571 |
| OngentysOpicapone | 12 | $10,548 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 284 | $6,706 |
| Rasagiline Mesylate | 41 | $6,070 |
| Rivastigmine | 44 | $5,833 |
| Entacapone | 18 | $4,597 |
| Primidone | 188 | $4,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $95,409 | $185,38680 claims |
| Amneal Pharmaceuticals LLCRytary | $2,166 | $143,410132 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $108 | $115,89225 claims |
| Acadia Pharmaceuticals IncNuplazid | $241 | $99,39223 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $254 | $86,08823 claims |
| UCB, Inc.Neupro | $51 | $25,52616 claims |
| Kyowa Kirin, Inc.Nourianz | $134 | $20,57111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Norfolk
- Ingrid Loma MillerNorfolk$364K
- Carmen FuentesNorfolk$339K
- Alice EdwardsNorfolk$111K
- Firas BeitinjanehNorfolk$31K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
- Jill CramerChristiansburg$598K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.